|
1
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hung CH, Chiu YC, Chen CH and Hu TH:
MicroRNAs in hepatocellular carcinoma: Carcinogenesis, progression,
and therapeutic target. Biomed Res Int. 2014:4864072014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong
Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes
in human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer Cell.
19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakao K, Miyaaki H and Ichikawa T:
Antitumor function of microRNA-122 against hepatocellular
carcinoma. J Gastroenterol. 49:589–593. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He XX, Chang Y, Meng FY, Wang MY, Xie QH,
Tang F, Li PY, Song YH and Lin JS: MicroRNA-375 targets AEG-1 in
hepatocellular carcinoma and suppresses liver cancer cell growth
in vitro and in vivo. Oncogene. 31:3357–3369. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu L, Beckebaum S, Iacob S, Wu G, Kaiser
GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, et al:
MicroRNA-101 inhibits human hepatocellular carcinoma progression
through EZH2 downregulation and increased cytostatic drug
sensitivity. J Hepatol. 60:590–598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sarkar D: AEG-1/MTDH/LYRIC in liver
cancer. Adv Cancer Res. 120:193–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak and Schmittgen: Analysis of relative
gene expression data using real-time quantitative PCR and the
2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scherr M, Venturini L, Battmer K,
Schaller-Schoenitz M, Schaefer D, Dallmann I, Ganser A and Eder M:
Lentivirus-mediated antagomir expression for specific inhibition of
miRNA function. Nucleic Acids Res. 35:e1492007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hata A and Lieberman J: Dysregulation of
microRNA biogenesis and gene silencing in cancer. Sci Signal.
8:re32015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tao J, Ji J, Li X, Ding N, Wu H, Liu Y,
Wang XW, Calvisi DF, Song G and Chen X: Distinct anti-oncogenic
effect of various microRNAs in different mouse models of liver
cancer. Oncotarget. 6:6977–6988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baek S, Cho KJ, Ju HL, Moon H, Choi SH,
Chung SI, Park JY, Choi KH, do Kim Y, Ahn SH, et al: Analysis of
miRNA expression patterns in human and mouse hepatocellular
carcinoma cells. Hepatol Res. 45:1331–1340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and
Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates
G1/S transition of human hepatocellular carcinoma cells.
Hepatology. 50:113–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang R, Zhao N, Li S, Fang JH, Chen MX,
Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses
angiogenesis and metastasis of hepatocellular carcinoma by
inhibiting the expression of VEGF, VAV2 and CDC42. Hepatology.
58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He XX, Kuang SZ, Liao JZ, Xu CR, Chang Y,
Wu YL, Gong J, Tian DA, Guo AY and Lin JS: The regulation of
microRNA expression by DNA methylation in hepatocellular carcinoma.
Mol Biosyst. 11:532–539. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He XX, Guo AY, Xu CR, Chang Y, Xiang GY,
Gong J, Dan ZL, Tian DA, Liao JZ and Lin JS: Bioinformatics
analysis identifies miR-221 as a core regulator in hepatocellular
carcinoma and its silencing suppresses tumor properties. Oncol Rep.
32:1200–1210. 2014.PubMed/NCBI
|
|
18
|
Guo H, Li W, Zheng T and Liu Z: MiR-195
targets HDGF to inhibit proliferation and invasion of NSCLC cells.
Tumour Biol. 35:8861–8866. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Wang Y, Lan H and Li J: MiR-195
inhibits the growth and metastasis of NSCLC cells by targeting
IGF1R. Tumour Biol. 35:8765–8770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa M
and Enokida H: The microRNA expression signature of bladder cancer
by deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fei X, Qi M, Wu B, Song Y, Wang Y and Li
T: MicroRNA-195-5p suppresses glucose uptake and proliferation of
human bladder cancer T24 cells by regulating GLUT3 expression. FEBS
Lett. 586:392–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang G, Wu D, Zhu J, Jiang O, Shi Q, Tian
J and Weng Y: Upregulation of miR-195 increases the sensitivity of
breast cancer cells to Adriamycin treatment through inhibition of
Raf-1. Oncol Rep. 30:877–889. 2013.PubMed/NCBI
|
|
23
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and
MiR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang L, Qian L, Li X and Yan J:
MicroRNA-195 inhibits colorectal cancer cell proliferation,
colony-formation and invasion through targeting CARMA3. Mol Med
Rep. 10:473–478. 2014.PubMed/NCBI
|
|
25
|
Ding J, Huang S, Wang Y, Tian Q, Zha R,
Shi H, Wang Q, Ge C, Chen T, Zhao Y, et al: Genome-wide screening
reveals that miR-195 targets the TNF-α/NF-κB pathway by
down-regulating IκB kinase alpha and TAB3 in hepatocellular
carcinoma. Hepatology. 58:654–666. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang X, Yu J, Yin J, Xiang Q, Tang H and
Lei X: MiR-195 regulates cell apoptosis of human hepatocellular
carcinoma cells by targeting LATS2. Pharmazie. 67:645–651.
2012.PubMed/NCBI
|
|
27
|
Amer M, Elhefnawi M, El-Ahwany E, Awad AF,
Gawad NA, Zada S and Tawab FM: Hsa-miR-195 targets PCMT1 in
hepatocellular carcinoma that increases tumor life span. Tumour
Biol. 35:11301–11309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Furuta M, Kozaki K, Tanimoto K, Tanaka S,
Arii S, Shimamura T, Niida A, Miyano S and Inazawa J: The
tumor-suppressive miR-497-195 cluster targets multiple cell-cycle
regulators in hepatocellular carcinoma. PLoS One. 8:e601552013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang HL, Yu H, Ma X, Xu D, Lin GF, Ma DY
and Jin JZ: MicroRNA-195 regulates steroid receptor coactivator-3
protein expression in hepatocellular carcinoma cells. Tumour Biol.
34:6955–6960. 2014. View Article : Google Scholar
|
|
30
|
Yang X, Yin J, Yu J, Xiang Q, Liu Y, Tang
S, Liao D, Zhu B, Zu X, Tang H and Lei X: MiRNA-195 sensitizes
human hepatocellular carcinoma cells to 5-FU by targeting BCL-w.
Oncol Rep. 27:250–257. 2012.PubMed/NCBI
|
